Nearly Half of Employers Have Dropped Pre-Hire Cannabis Testing

Photo by Ron Lach via Pexels.

Nearly half of employers surveyed by the law firm Fisher Phillips say they've stopped screening job applicants for cannabis before hiring them. That's the headline number from an FP Flash Survey that polled almost 1,000 employers nationwide, and it's a striking shift from the era when a pre-employment piss test was just a routine box to check between the job offer and the first day. The survey itself is a bit older than the current headlines suggest -- it was fielded in late 2024 -- but it got a fresh round of attention in July 2026 after the Wall Street Journal ran a piece pairing those numbers with newly released 2025 Quest Diagnostics testing data.

What makes the pairing interesting is that it's not really a story about employers suddenly embracing cannabis reform. Most of the employers dropping the test aren't doing it because they've had a change of heart about marijuana use. They're doing it because a tight labor market punishes anyone who narrows their applicant pool for no operational reason. And that creates a real tension worth sitting with: fewer companies are testing applicants at the door, even as the people who do get tested are coming back positive at higher rates than they used to. Something is shifting on both sides of that equation, and it's worth pulling apart what's actually driving each half.

What the Survey Actually Found

Photo by Vitaly Gariev via Unsplash.

The FP Flash Survey ran from September 23 to October 2, 2024, and drew responses from nearly 1,000 employers across a range of industries and company sizes. The topline result: 48% said cannabis is no longer part of their pre-hire screening process at all. That's not a fringe result buried in a footnote -- it's essentially half of the market walking away from a practice that was, for decades, treated as standard due diligence.

When Fisher Phillips asked why, the answer wasn't a philosophical conversion. Respondents pointed overwhelmingly to talent acquisition and retention pressures -- a polite way of saying they couldn't afford to lose qualified candidates over a positive result for a drug that's legal, medically or recreationally, in a majority of states. Several large, recognizable employers have already made this call publicly for their non-safety-sensitive roles, including Amazon, Citigroup, Home Depot, and AutoNation. None of those companies abandoned testing across the board -- warehouse forklift operators and delivery drivers are a different conversation -- but for office staff, retail associates, and other roles without an obvious safety component, the calculus has changed.

Attorney Todd Logsdon, quoted in the Journal's coverage, described employers as becoming much more surgical about where they still apply testing. Rather than a blanket policy covering every new hire, companies are increasingly asking a narrower question: does this specific job actually require it? Logsdon's read is that broad-based testing has simply become a liability in recruiting terms -- it shrinks the pool of otherwise qualified applicants without a clear corresponding benefit, especially for roles where nobody is operating machinery, driving a vehicle, or working in a regulated safety capacity.

Why the Employers Who Still Test Are Wavering

Half the market moving away from pre-hire testing doesn't mean the other half is settled on keeping it. Among employers who still test applicants, the survey found 81% cite safety concerns as their primary justification, with 51% pointing to legal or regulatory compliance obligations. Those are legitimate, defensible reasons -- nobody wants a forklift operator or a heavy-equipment technician showing up impaired. But the survey also caught something less obvious underneath those numbers: only 49% of employers still testing said they're firmly committed to keeping the practice in place going forward.

That's barely half of an already-shrinking group. Another 22% said they're actively considering loosening their policy, and 29% said they simply aren't sure what they'll do. Put those numbers together and the picture that emerges isn't a stable equilibrium -- it's a slow-motion exodus. If roughly half of the remaining testers are wavering or actively reconsidering, the 48% figure that made headlines in 2024 looks less like a ceiling and more like a waypoint on the way to something higher.

There's an important carve-out here, though. Industries bound by federal safety regulations -- trucking and transportation, aviation, rail, and much of construction -- aren't part of this drift, because they're not really making a discretionary choice. Federal rules under agencies like the Department of Transportation require drug testing regardless of what state law says about legalization, and cannabis's federal Schedule I status keeps those mandates locked in place. So while general office and retail employers are quietly stepping back from testing, the safety-sensitive sector remains anchored exactly where it's always been.

The Twist: Positivity Rates Are Actually Rising

Here's the part that complicates any tidy narrative about cannabis normalization: while fewer employers are testing, the people who do get tested are failing at meaningfully higher rates than they were a few years ago. Quest Diagnostics' 2025 Drug Testing Index put urine test marijuana positivity at 4.4%, up from 3.9% in 2021. That's a modest-looking jump in raw percentage terms, but it represents a real, sustained climb rather than statistical noise.

The hair-testing numbers are more dramatic. According to the National Law Review's analysis of the same Quest data, hair test positivity hit roughly 15% in 2025 -- a jump of nearly 60% since 2021. Random hair screenings, which aren't triggered by an incident or a specific suspicion but simply pulled from an existing workforce, came back positive at about 21%, the highest rate of any testing category Quest tracks. Fisher Phillips ran its own read on the same five-year window and landed on a similar trajectory: hair-test positivity climbing from roughly 10% in 2021 to 15% in 2025, close to a 50% increase.

These two trends -- fewer employers looking, and higher positivity among those who still do -- aren't actually in tension with each other once you think about who's left in the testing pool. As legalization spreads and casual use becomes more normalized among the general working population, the baseline rate of cannabis use among job applicants and employees climbs right along with public opinion. Employers who've dropped pre-hire testing have simply removed themselves from that measurement entirely, while the employers still testing are sampling from a population that uses cannabis more than it did five years ago. It's less a contradiction than two sides of the same underlying shift in consumption patterns.

Why Urine Screens Don't Actually Measure Impairment

Photo by Markus Spiske via Unsplash.

NORML Deputy Director Paul Armentano has described pre-hire urine screening as a relic of a much older, cruder era of drug policy, and the science backs him up on the mechanics. A standard urine test doesn't detect THC, the psychoactive compound that actually produces intoxication. It detects carboxy-THC, an inert metabolite the body produces after THC has already been metabolized and has left the bloodstream in any pharmacologically active form.

The problem is timing. Carboxy-THC can linger in urine for days after occasional use, and for regular or heavy users, it can be detectable for weeks or, in some documented cases, even months after the last time they actually consumed cannabis. None of that window has anything to do with whether the person was impaired on the day of the test, or the day before, or three weeks before. A positive result tells an employer only that cannabis was used at some point in the recent past -- it says nothing about current intoxication, judgment, or job performance.

Armentano points to research on off-hours cannabis consumers showing they perform no differently on the job than non-using peers and don't carry elevated safety risk in workplace settings generally. That's a meaningful distinction from, say, alcohol, where blood tests can be timed to actual impairment. Cannabis metabolite testing simply can't make that distinction with any precision.

This is likely a bigger driver of the employer shift than most coverage credits. Companies focused on filling roles quickly and keeping good workers aren't just responding to a labor shortage in the abstract -- they're increasingly aware that testing for non-safety roles catches a lot of people who used cannabis on a Friday night and were never impaired at work, while providing essentially no useful signal about who's actually a risk on the job.

The Bigger Picture: Public Opinion and Legal Landscape

Photo by sarangib via Pixabay.

Public attitudes have moved a long way from where they were even a decade ago. A 2026 Pew Research Center survey found that just 11% of American adults now believe cannabis should be illegal for all purposes -- a small enough share that opposition to legalization in any form has become the minority position by a wide margin. That shift in public opinion has tracked alongside, and probably reinforced, the steady expansion of state-level legalization, and a growing number of states have gone further by passing employment protections that limit adverse action against workers for off-duty cannabis use.

Federal law hasn't caught up to any of this. Cannabis remains a Schedule I controlled substance under federal law, and that classification is exactly why safety-sensitive and federally regulated positions keep mandatory testing regimes in place no matter what a given state has done on legalization. A trucking company operating across state lines doesn't get to opt out of DOT testing requirements because its home state legalized recreational use.

The result is a genuinely patchwork landscape. Policy varies significantly not just state to state but industry to industry, and the rules that apply to a warehouse job in one state may look nothing like the rules for the same job title two states over. Anyone navigating this as a job seeker, or setting policy as an employer, needs to check current local law rather than assume there's one national standard -- because there isn't, and reference to a general trend like the one described here shouldn't substitute for confirming the specifics that apply in a given state or industry.

Taken together, the employer shift away from pre-hire testing looks less like an ideological realignment and more like a practical adjustment to labor market pressure that happens to be moving in the same direction as public opinion. The two forces are reinforcing each other, even if they didn't start from the same place.

Strip away the framing and what's really happening is an economics story that happens to overlap with a culture story. Employers aren't dropping pre-hire cannabis testing because HR departments have collectively decided the science around impairment finally caught up with policy, even though it has. They're dropping it because a tight labor market makes it expensive to disqualify otherwise-qualified candidates over a test that can't distinguish a Saturday-night edible from a Tuesday-morning safety risk.

The trajectory looks fairly clear from here. With only 49% of the employers still testing describing themselves as firmly committed to the practice, and roughly half of that remaining group either actively reconsidering or openly unsure, pre-hire cannabis screening for ordinary office and retail jobs is on a slow but steady path toward becoming the exception rather than the norm. That doesn't mean testing disappears -- it means it increasingly gets reserved for roles where there's an actual operational reason to ask the question.

Safety-sensitive industries aren't part of that drift and won't be anytime soon, since federal mandates in transportation, aviation, and similar sectors don't bend to state legalization votes or employer preference. Expect a durable two-tier system: mandatory testing bound tightly to safety-critical work, and a shrinking, increasingly optional practice everywhere else, with the line between the two drawn less by ideology than by who's actually operating heavy equipment for a living.